Influenza a(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019

Eurosurveillance

Volumn 24, Issue 12, 2019, Pages

  Takashita, Emi ^a   Kawakami, Chiharu ^b   Ogawa, Rie ^a   Morita, Hiroko ^a   Fujisaki, Seiichiro ^a   Shirakura, Masayuki ^a   Miura, Hideka ^a   Nakamura, Kazuya ^a   Kishida, Noriko ^a   Kuwahara, Tomoko ^a   Ota, Akira ^c   Togashi, Hayato ^c   Saito, Ayako ^d   Mitamura, Keiko ^e   Abe, Takashi ^f   Ichikawa, Masataka ^g   Yamazaki, Masahiko ^h   Watanabe, Shinji ^a   Odagiri, Takato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Yokohama City Institute of Health   (Japan)

^c SAISEIKAI YOKOHAMASHI NANBU HOSPITAL   (Japan)

^d Saito Children s Clinic   (Japan)

^e Public Interest Foundation Corporation Life Extension Laboratory Attached Eiju General Hospital   (Japan)

^f Abe Clinic   (Japan)

^g Ichikawa Children's Clinic   (Japan)

^h Zama Children's Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BALOXAVIR MARBOXIL; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; BALOXAVIR; ENZYME INHIBITOR; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE; THIEPIN DERIVATIVE; TRIAZINE DERIVATIVE;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DISEASE TRANSMISSION; DRUG MONITORING; FACE EDEMA; FEVER; HOSPITALIZATION; HOSPITALIZED CHILD; HUMAN; INFLUENZA A (H3N2); INFLUENZA A VIRUS; INFLUENZA A VIRUS (A YOKOHAMA 87 2019(H3N2)); INFLUENZA A VIRUS (A YOKOHAMA 88 2019(H3N2)); JAPAN; NONHUMAN; ONSET AGE; VIRUS DETECTION; VIRUS ISOLATION; ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; CHILD; DRUG EFFECT; GENETICS; HOSPITAL PATIENT; INFLUENZA; INFLUENZA A VIRUS (H3N2); ISOLATION AND PURIFICATION; MIDDLE AGED; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; INPATIENTS; JAPAN; MIDDLE AGED; OXAZINES; POLYMERASE CHAIN REACTION; PYRIDINES; THIEPINS; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 85063934265     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2019.24.12.1900170     Document Type: Article

References (9)

1. Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, et al. On Behalf Of The Influenza Virus Surveillance Group Of Japan. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019;24(3). https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800698 PMID: 30670142
2. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633. https://doi.org/10.1038/s41598-018-27890-4 PMID: 29941893
3. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front Microbiol. 2018;9(3026):3026. https://doi. org/10.3389/fmicb.2018.03026 PMID: 30574137
4. Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill. 2019;24(3). https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800666 PMID: 30670144
5. World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87(39):369-74. PMID: 23061103
6. Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, et al. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Influenza and Other Infections; 2019 February 19-20; Tokyo, Japan.
7. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018;379(10):913-23. https://doi.org/10.1056/NEJMoa1716197 PMID: 30184455
8. Koszalka P, Tilmanis D, Roe M, Vijaykrishna D, Hurt AC. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018. Antiviral Res. 2019;164:91-6. https://doi.org/10.1016/j.antiviral.2019.02.007 PMID: 30771405
9. National Institute of Infectious Diseases (NIID). Antiviral resistance surveillance in Japan. Tokyo: NIID. Available from: http://www.nih.go.jp/niid/en/influ-resist-e.html